Check the effectiveness of colorectal cancer immune cancer treatment with 'Leovirus'
Nov 26, 2024
A research team led by Kim Chan, Jeon Hong-jae, a professor of hematologic oncology at Bundang Cha Hospital (Director Yoon Sang-wook) at Cha Medical University, and Lee Won-seok, a research team led by research professors, published the results of a study that found that the eating (or oral) anticancer reovirus is used to reconstruct the intestinal microbiome (microbial system) to effectively induce anticancer immune responses.
The study was conducted in collaboration with a research team at the University of Ottawa in Canada and published in the latest issue of the international renowned academic journal 'Nature Communications (IF=14.7)'.
Anticancer virus is an anticancer treatment that selectively infects and destroys cancer cells and triggers an anticancer immune response. Leovirus, one of these, has been administered through injection or intravenous injection in preclinical and clinical trials of various carcinomas. However, due to difficulties in injecting viral drugs and limitations such as blood inactivation, it was difficult to derive satisfactory treatment effects in cancer patients.
In response, the research team of professors Kim Chan and Jeon Hong-jae confirmed that oral administration of leovirus has an anticancer effect that is more than three times superior to direct administration of the tumor in the case of multiple tumors. In particular, it was confirmed that orally administered anti-cancer leovirus interacts with the immune system in Peyer's patch located at the end of the small intestine and increases immunoglobulin A (IgA) antibody secretion cells in the small intestine mucosa through special intestinal blood vessels expressing mucosal protein cell adhesion molecules. As a result, it was confirmed that IgA antibodies secreted into the intestine reconstruct the intestinal microbiome to enhance the anticancer immune response inside the tumor.
In particular, CD8 T cells, killer cells that attack colorectal cancer, more than doubled in number compared to the control group during chemotherapy. Furthermore, when oral anticancer reovirus was combined with PD-1 and CTLA-4 immune checkpoint inhibitors in a model of colon cancer mice, it was effective in inducing complete remission of tumors and forming continuous anticancer immunity.
Professor Kim Chan of Bundang Cha Hospital said, "This study showed that oral anti-cancer reovirus is an effective and powerful anti-cancer immune treatment strategy, and through this, it is a meaningful study that suggests the possibility of new cancer treatments. Administration of oral anti-cancer viruses is expected to be particularly effective against digestive cancers such as colon cancer and liver cancer."
This study was conducted with the support of the Ministry of Science and ICT and the Korea Research Foundation's mid-sized research support project.
The study was conducted in collaboration with a research team at the University of Ottawa in Canada and published in the latest issue of the international renowned academic journal 'Nature Communications (IF=14.7)'.
Anticancer virus is an anticancer treatment that selectively infects and destroys cancer cells and triggers an anticancer immune response. Leovirus, one of these, has been administered through injection or intravenous injection in preclinical and clinical trials of various carcinomas. However, due to difficulties in injecting viral drugs and limitations such as blood inactivation, it was difficult to derive satisfactory treatment effects in cancer patients.
In response, the research team of professors Kim Chan and Jeon Hong-jae confirmed that oral administration of leovirus has an anticancer effect that is more than three times superior to direct administration of the tumor in the case of multiple tumors. In particular, it was confirmed that orally administered anti-cancer leovirus interacts with the immune system in Peyer's patch located at the end of the small intestine and increases immunoglobulin A (IgA) antibody secretion cells in the small intestine mucosa through special intestinal blood vessels expressing mucosal protein cell adhesion molecules. As a result, it was confirmed that IgA antibodies secreted into the intestine reconstruct the intestinal microbiome to enhance the anticancer immune response inside the tumor.
In particular, CD8 T cells, killer cells that attack colorectal cancer, more than doubled in number compared to the control group during chemotherapy. Furthermore, when oral anticancer reovirus was combined with PD-1 and CTLA-4 immune checkpoint inhibitors in a model of colon cancer mice, it was effective in inducing complete remission of tumors and forming continuous anticancer immunity.
Professor Kim Chan of Bundang Cha Hospital said, "This study showed that oral anti-cancer reovirus is an effective and powerful anti-cancer immune treatment strategy, and through this, it is a meaningful study that suggests the possibility of new cancer treatments. Administration of oral anti-cancer viruses is expected to be particularly effective against digestive cancers such as colon cancer and liver cancer."
This study was conducted with the support of the Ministry of Science and ICT and the Korea Research Foundation's mid-sized research support project.
|
bellho@sportschosun.com
